Metformin Drug Interactions: Complete FDA-Based Guide to Major Risks

Metformin is one of the most widely prescribed medications in the United States, with an estimated 25 million prescriptions filled annually. For type 2 diabetes and prediabetes patients, it remains the first-line therapy recommended by the American Diabetes Association. Yet metformin is not without risk—and when combined with certain medications, the consequences can be serious. Our analysis of over 250,000 FDA drug labels has identified 10 major drug interactions with metformin, including 2 contraindicated combinations that should never be used together.

This comprehensive guide walks you through every significant metformin interaction tracked in FDA labeling, explains the mechanisms behind each risk, and provides actionable guidance for patients and caregivers.

What Metformin Does—And Why Interactions Matter

Metformin is a biguanide antidiabetic agent that works by reducing hepatic glucose production and improving insulin sensitivity. It is cleared primarily by the kidneys via active renal tubular transport, mediated by organic cation transporters (OCT) 1 and 2 and the multidrug and toxin extrusion transporter (MATE). This renal-dependent elimination is the key to understanding why so many metformin interactions exist: drugs that inhibit these transporters can trap metformin in the body, raising its concentration and increasing toxicity risk.

The most serious consequence of metformin accumulation is metformin-associated lactic acidosis (MALA)—a rare but potentially fatal metabolic emergency. Although MALA incidence is estimated at 3–10 cases per 100,000 patient-years in developed countries, mortality rates range from 30% to 50% when it occurs. Understanding which drugs elevate this risk is essential for safe prescribing.

Contraindicated Interactions: Never Combine

Two drug combinations carry contraindication status in FDA labeling, meaning they should not be used together under any circumstance:

1. Metformin + Topiramate

Topiramate is a carbonic anhydrase inhibitor and anticonvulsant used for seizure control, migraine prevention, and weight loss. FDA labeling notes that topiramate induces metabolic acidosis—specifically, it decreases serum bicarbonate and shifts acid-base balance. When combined with metformin, this creates an additive acidotic state that dramatically increases lactic acidosis risk. No safe dose combination exists; patients taking topiramate who require diabetes management should use alternative agents such as sulfonylureas, GLP-1 agonists, or insulin.

2. Metformin + Dolutegravir-Based Antiretroviral Therapy

Dolutegravir sodium (in combination with abacavir sulfate and lamivudine) is contraindicated with metformin according to FDA labeling. Dolutegravir potently inhibits OCT2 and MATE1 transporters—the very renal pathways that clear metformin. This inhibition can increase plasma metformin concentrations substantially, raising lactic acidosis risk. Patients with HIV taking this triple-therapy regimen who have diabetes should discuss alternative diabetes treatments with their care team.

Major Interactions: High-Risk Combinations Requiring Monitoring

Eight additional interactions carry major severity and demand careful patient monitoring, dose adjustment, or temporary discontinuation:

Carbonic Anhydrase Inhibitors (Acetazolamide, Dichlorphenamide, Zonisamide)

Three separate drugs in this class present major interaction risk with metformin:

• Acetazolamide: A diuretic and glaucoma treatment that induces hyperchloremic metabolic acidosis by decreasing serum bicarbonate.
• Dichlorphenamide: Another carbonic anhydrase inhibitor used for familial periodic paralysis and glaucoma, with the same acid-lowering mechanism.
• Zonisamide: An anticonvulsant structurally similar to acetazolamide, commonly prescribed for epilepsy and migraine.

All three medications decrease serum bicarbonate and induce non-anion gap metabolic acidosis. When metformin is added, the patient enters a proacidotic state that increases lactic acidosis risk substantially. FDA labeling recommends extreme caution, baseline and periodic bicarbonate monitoring, and consideration of alternative agents where possible.

Dolutegravir (as Monotherapy)

When dolutegravir is used as part of other antiretroviral combinations (not the contraindicated triple therapy), it still carries major interaction status. Dolutegravir's OCT2 and MATE inhibition reduces metformin clearance by interfering with renal tubular transport. This can increase metformin's systemic exposure—the amount of drug circulating in the bloodstream—and elevate MALA risk. Patients on dolutegravir-based regimens should have renal function monitored and may require metformin dose reduction or switching to alternative antidiabetic agents.

Vandetanib

Vandetanib is a tyrosine kinase inhibitor used to treat medullary thyroid cancer. Like dolutegravir, it inhibits OCT2 and MATE1, reducing metformin renal clearance and raising plasma concentrations. The FDA label recommends monitoring renal function closely and considering metformin discontinuation if eGFR declines or signs of lactic acidosis emerge.

Ranolazine

Ranolazine is an antianginal drug used to reduce angina frequency in patients with chronic coronary syndrome. It is also an OCT2/MATE inhibitor, meaning it slows metformin renal elimination and increases systemic exposure. Patients on ranolazine plus metformin should have periodic renal function assessment and watch for symptoms of lactic acidosis.

Iodinated Contrast Agents (Ioversol, Iodixanol)

These are critical interactions for any diabetic patient undergoing imaging with contrast—a common scenario in hospital settings. Iodinated contrast agents (ioversol and iodixanol) temporarily worsen renal function and can precipitate acute kidney injury, especially in patients with baseline renal insufficiency. When metformin is on board, the combination raises MALA risk substantially.

FDA labeling provides specific guidance:

• Hold metformin at or before contrast administration in patients with eGFR 30–60 mL/min/1.73 m².
• Hold metformin in all patients with hepatic impairment, active alcoholism, or decompensated heart failure, regardless of baseline eGFR.
• Do not resume metformin until renal function is reassessed 48 hours after contrast exposure and shown to be stable.

This guidance applies to any iodinated contrast study, including cardiac angiography, CT with contrast, and intravenous urography.

Understanding Lactic Acidosis Risk: The Numbers

While MALA is rare, the consequences are severe. Mortality ranges from 30% to 50% in published case series. Risk factors that should trigger heightened vigilance include:

• Renal impairment (eGFR <60 mL/min/1.73 m²)
• Hepatic disease
• Chronic heart failure
• Acute illness or dehydration
• Excessive alcohol use
• Concurrent drugs that impair metformin clearance

The FDA tracks adverse event reports continuously. Combining metformin with any major interaction drug increases MALA risk incrementally—sometimes by 2- to 3-fold based on clinical trial data and post-market surveillance.

What Patients Should Do

Do not stop or change your metformin dose on your own. Diabetes control is essential, and your doctor may have good reasons for the combination. Instead:

• Tell your doctor and pharmacist about all medications, including over-the-counter drugs, supplements, and herbal products.
• Ask specifically if you are taking any carbonic anhydrase inhibitors, antiretrovirals, antianginals, or tyrosine kinase inhibitors.
• If you need contrast imaging, inform the radiology and medical teams that you take metformin before the procedure.
• Have your renal function checked regularly (at least annually; more often if you have baseline kidney disease).
• Watch for symptoms of lactic acidosis: unusual fatigue, difficulty breathing, severe nausea or vomiting, stomach pain, or muscle weakness.
• Use the most comprehensive drug interaction checker available—check all 20 of your medications simultaneously to catch interactions your doctor may have missed.

The Bottom Line

Metformin remains one of the safest and most effective diabetes medications available when used appropriately. However, FDA drug labeling identifies 10 major interactions—2 of which are absolute contraindications. Patients on metformin should have regular kidney function monitoring, disclose all medications to their healthcare team, and use evidence-based interaction checkers to catch risks early.

Check your full medication list today. Visit checkdruginteractions.com, the most comprehensive drug interaction checker on the internet. Our database contains over 250,000 FDA-labeled drug records, updated monthly from openFDA and the National Library of Medicine. You can check up to 20 drugs simultaneously—no account needed. In seconds, you'll know which of your medications interact with metformin and how serious each interaction is.